Fig. 8

Anti-psoriasis pharmacodynamics. a PASI scoring for erythema; b PASI scoring for scaling; c PASI scoring for skin thickening (mean ± SD, n = 5; ^*p < 0.05, ^**p < 0.01, ^***p < 0.001 compared with IMQ group; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 compared with TRA-BT-FNL-Gel group; d representative photos of spleens in different group; e the changes of spleen weight in different groups, (mean ± SD, n = 5; ^*p < 0.05, **p < 0.01, ***p < 0.001 compared with the weight of control group); f expression levels of TNF-α in different group,(g) Expression levels of IL-6 in in different group, (mean ± SD, n = 5; ^*p < 0.05, ^**p < 0.01, ^***p < 0.001 compared with control group; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 compared with IMQ group, ^@p < 0.05, ^@@p < 0.01, ^@@@p < 0.001 compared with TRA-BT-FNL-Gel group